Compare Neurocrine Biosciences Inc (NBIX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wells Fargo & Co — how do they compare? Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B), while Wells Fargo & Co trades at $82.72 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 17.3× Neurocrine Biosciences Inc's market cap, and Wells Fargo & Co pays a 2.44% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Wells Fargo & Co for 87 Days on average.
| NBIX | WFC | |
|---|---|---|
Market Cap | $14.36B | $248.06B |
Volume | 1,237,180 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $185.50 | $96.40 |
52-Week Low | $123.10 | $73.42 |
Typical Hold Time | 23 Days | 87 Days |
Enterprise Value | $14.37B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Wells Fargo (WFC) trades at $80.26, down 1.53% today, with a bearish technical signal despite recent earnings beat in Q2 2026. The company shows strong fundamentals with a P/E of 11.92, net income margin of 25.97%, and a recent credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01). Revenue growth is steady, reaching $83.70B in 2025, with a consensus price target of $99.13 suggesting upside potential.
The stock presents a value opportunity with attractive valuation metrics and improving profitability, but faces risks from volatile cash flows and regulatory changes in bank stress tests. Analyst sentiment is mixed with 46.66% buy ratings, while technical indicators signal near-term caution. Upside hinges on Q3 2026 earnings meeting expectations of $1.85 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
